Skip to main content
OpenTrials
Completed

NCT Number: NCT00764244

Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema

Macular edema is the main cause of vision loss in diabetic patients. Its treatment is mainly based on laser photocoagulation, but has limited results. Alternative treatment are under investigation, such as vitrectomy and intravitreal injections of triamcinolone .The aim of VITRILASE is to compare the efficacy of these two treatments to laser photocoagulation for diabetic macular edema.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pascale MASSIN

Paris, 75010, France

About this study

It is a randomized study with three arms

  • vitrectomy
  • repeat intravitreal triamcinolone injections
  • laser photocoagulation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with type 1 or type 2 diabetes
  • Visual acuity (VA) : 0.1≤ VA < 0.5 (35 ≤ ETDRS score < 70)
  • Patient with diffuse diabetic macular edema , as defined by :§ Retinal thickening involving the center of the macular on biomicroscopy§ AND diffuse leakage on fluorescein angiography .
  • Macular thickness in the central area 1000 µm in diameter ³ 300 µm.
  • Patient with :· Either diffuse diabetic macular edema · Or combined diffuse and focal diabetic macular edema with persistent diffuse macular edema 6 months after laser treatment of the focal edema .
  • Systolic blood pressure ≤ 160 mmHg and diastolic blood pressure ≤ 90 mmHg.,
  • HbA1c < 10%.

Exclusion criteria

  • Patient with tractional diabetic macular edema, as defined by· A taut, thickened posterior hyaloid on biomicroscopy AND/OR· a thickened , highly reflective posterior hyaloid on OCT , partially detached from the posterior pole, and exerting a traction on the macula
  • Active proliferative diabetic retinopathy (ETDRS stage 61 or more severe)
  • Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or organized central hard exudate plaque³ 1 disk area
  • Hypertensive retinopathy
  • Epiretinal membrane.
  • Rubeosis irides .
  • Patient requiring immediate panretinal photocoagulation or panretinal photocoagulation performed within the past 6 months .
  • History of chronic glaucoma in the study eye
  • History of elevated intraocular pressure ≥30 mm Hg and/or alteration of visual field
  • Concomitant therapy with systemic or topical ocular corticosteroids within the last 15 days .
  • Cataract surgery in the study eye within the past 6 months, Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within the past 6 months,
  • Aphakia
  • Patient with pseudophakic macula edema
  • Unstable medical status including glycemic control and blood pressure. Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) should not be enrolled.
  • Chronic renal failure
  • Pregnant or nursing (lactating) women

Treatment and study plan

Vitrectomy

Procedure

Vitrectomy

Intravitreal triamcinolone injections

Drug

Intravitreal triamcinolone injections

Other names: - KENACORT RETARD, - Triamcinolone Acetonid

Laser Photocoagulation

Procedure

Laser photocoagulation

Primary outcomes

  1. Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years

    Time frame: at 2 years

Secondary outcomes

  1. Central macular thickness on Optical Coherence Tomography (OCT)

    Time frame: at 8, 12 and 24 months

  2. Percentage of patients with visual gain ≥ 3 ETDRS lines

    Time frame: 8, 12 and 22 months

  3. Progression of lens opacities

    Time frame: During the all follow-up

  4. Frequency of complications

    Time frame: During the all follow-up

  5. Results analysis according to preoperative vitreous detachment, honeycomb macular edema on fluorescein angiography

    Time frame: at inclusion time

  6. Evolution of visual fiends and posterior vitreous detachment

    Time frame: At inclusion time and 2 years

  7. Percentage of patients presenting an increase of 2 line or more of best corrected visual acuity on ETDRS charts

    Time frame: after 1 year, 22 months and 24 months of follow-up

  8. Percentage of patients presenting an decrease of 2 line or more of best corrected visual acuity on ETDRS charts

    Time frame: after 1 year, 22 months and 24 months of follow-up

  9. Scores ETDRS

    Time frame: after 1 year, 22 months and 24 months of follow-up

  10. Mean best corrected visual acuity during follow-up period

    Time frame: during the all follow-up

  11. Progression of retinopathy diabetic in each group

    Time frame: during the all follow-up

  12. Outcome in respect to posterior vitreal detachment (PVD) stage

    Time frame: during the all follow-up

  13. PVD stage evolution during the follow-yp in laser and triamcinolone group

    Time frame: first and last exam

  14. Evolution of visual field in each group

    Time frame: inclusion and last visit

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema

Acronym: VITRILASE

Important dates

Study start
2005
Primary completion
2009
Study completion
2009
First posted
Oct 1, 2008
Registry last updated
Mar 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.